Jane Street’s Immuneering IMRX Stock Holding History

Jane Street’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$916K	Buy	183,500 +148,900	+430%	+$753K	﹤0.01%	6726
2026 Q1	$182K	Sell	34,600 -28,200	-45%	-$145K	﹤0.01%	10238
2025 Q4	$413K	Buy	+62,800	New	+$403K	﹤0.01%	8125

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Jane Street's IMRX Position: Q2 2026 in Review

Jane Street sold out of Immuneering (IMRX) in Q2 2026, closing a stake of 77,414 shares — an estimated $392K sold.

Jane Street first reported a position in IMRX in Q1 2023 and held it in 6 quarters. The position peaked at $671K in Q4 2025. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

Jane Street reported no remaining Immuneering position as of Q2 2026 after selling out during the quarter.
Jane Street sold 77,414 Immuneering shares in Q2 2026, an estimated $392K.
Jane Street first reported a position in Immuneering in Q1 2023 and held it in 6 quarters.
Jane Street's Immuneering position peaked at $671K in Q4 2025.
112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.